Johnson & Johnson (JNJ) Stock Analysis
This is a peer-relative look at Johnson & Johnson (JNJ): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.
Company Profile
| Profile Item | JNJ |
|---|---|
| Name | Johnson & Johnson |
| Country/Region | United States |
| GICS Sector | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals |
| Market Capitalization | 603.27 billion USD |
| Currency | USD |
| Exchange | NYSE |
| Listing Date | January 2, 1962 |
| Security Type | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | Current stock: JNJ | Industry group median |
|---|---|---|
| Total Return (1Y) | 56.29% | 47.89% |
| Total Return (3Y, Annualized) | 17.14% | 9.98% |
| Total Return (5Y, Annualized) | 11.22% | -4.89% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | Current stock: JNJ | Industry group median |
|---|---|---|
| Volatility (1Y, Annualized) | 18.09% | 69.09% |
| Beta (5Y) | 0.24 | 0.91 |
| Max Drawdown (5Y) | -18.41% | -82.64% |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | Current stock: JNJ | Industry group median |
|---|---|---|
| Sharpe Ratio (1Y) | 2.89 | 0.81 |
| Sortino Ratio (1Y) | 4.86 | 1.37 |
Profitability
ROE (TTM)
No usable ROE is available for Johnson & Johnson (JNJ) this period, so the shareholder-equity return read is skipped.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 99.40%
- Q3
- 2.50%
- Median
- -31.42%
- Q1
- -62.21%
- Min
- -157.07%
- JNJ
- --
Largest peers
- LLY
- 107.46%
- NVO
- 71.40%
- NVS
- 34.93%
- AZN
- 23.48%
- MRK
- 18.94%
- JNJ
- --
- ABBV
- --
Net Margin (TTM)
Johnson & Johnson (JNJ) keeps 21.48% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.48%
Group distribution
- JNJ
- 21.48%
- Max
- 11.75%
- Q3
- 2.69%
- Median
- 0.00%
- Q1
- -3.38%
- Min
- -11.53%
Largest peers
- NVO
- 37.21%
- LLY
- 34.99%
- NVS
- 23.92%
- JNJ
- 21.48%
- AZN
- 17.19%
- MRK
- 13.59%
- ABBV
- 5.79%
Operating Margin (TTM)
Johnson & Johnson (JNJ) turns 28.61% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.61%
Group distribution
- Max
- 100.30%
- JNJ
- 28.61%
- Q3
- 4.66%
- Median
- 0.00%
- Q1
- -121.08%
- Min
- -309.54%
Largest peers
- NVO
- 61.57%
- LLY
- 49.39%
- MRK
- 38.60%
- ABBV
- 32.16%
- NVS
- 30.48%
- JNJ
- 28.61%
- AZN
- 27.94%
Profitability Metrics
| Metric | Current stock: JNJ | Industry group median |
|---|---|---|
| ROE (TTM) | -- | -31.42% |
| ROA (TTM) | -- | -15.76% |
| Net Margin (TTM) | 21.48% | 0.00% |
| Operating Margin (TTM) | 28.61% | 0.00% |
| Gross Margin (TTM) | 68.10% | 30.12% |
Growth
Revenue Growth
Johnson & Johnson (JNJ) grew revenue 6.05%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.
EPS Growth
Johnson & Johnson (JNJ) grew earnings per share 90.50%, in the upper peer quartile. Per-share profits are compounding faster than at most industry peers.
Growth Metrics
| Metric | Current stock: JNJ | Industry group median |
|---|---|---|
| Revenue Growth (YoY) | 6.05% | 11.61% |
| Revenue Growth (3Y CAGR) | 5.60% | 10.74% |
| EPS Growth (YoY) | 90.50% | 1.77% |
| EPS Growth (3Y CAGR) | 17.90% | 3.04% |
Financial Strength
Current Ratio (MRQ)
No usable current ratio is available for Johnson & Johnson (JNJ) this period, so the short-term liquidity read is skipped.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 26.16
- Q3
- 12.33
- Median
- 5.81
- Q1
- 2.71
- Min
- 0.28
- JNJ
- --
Largest peers
- LLY
- 1.50
- MRK
- 1.30
- AZN
- 0.91
- NVS
- 0.85
- ABBV
- 0.80
- NVO
- 0.79
- JNJ
- --
Debt / Equity (MRQ)
Johnson & Johnson (JNJ) has debt-to-equity ratio of 0.68, roughly in line with the peer group’s normal leverage range. Its mix of debt and equity looks typical for the industry.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.68
Group distribution
- Max
- 1.60
- Q3
- 0.68
- JNJ
- 0.68
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Largest peers
- LLY
- 1.39
- NVS
- 1.21
- MRK
- 1.07
- NVO
- 0.72
- AZN
- 0.72
- JNJ
- 0.68
- ABBV
- --
Financial Strength Metrics
| Metric | Current stock: JNJ | Industry group median |
|---|---|---|
| Current Ratio (MRQ) | -- | 5.81 |
| Debt / Equity (MRQ) | 0.68 | 0.15 |
| Net Debt / EBITDA | 0.95 | 1.05 |
Dividends
Dividend Yield (TTM)
Johnson & Johnson (JNJ) has dividend yield of 2.11%, above the entire industry range. That headline income is large, but yields this far above peers often come from a falling share price or an at-risk payout, so dividend safety matters more than the percentage itself.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.11%
Group distribution
- JNJ
- 2.11%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- NVO
- 23.58%
- ABBV
- 2.66%
- MRK
- 2.64%
- JNJ
- 2.11%
- AZN
- 1.95%
- LLY
- 0.54%
- NVS
- 0.00%
Dividend Payout Ratio (TTM)
Johnson & Johnson (JNJ) has payout ratio of 60.79%, above the peer distribution for its industry. The dividend consumes more reported earnings than peers normally do, leaving unusually thin earnings cover.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
60.79%
Group distribution
- JNJ
- 60.79%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- ABBV
- 325.98%
- MRK
- 93.52%
- NVS
- 67.91%
- JNJ
- 60.79%
- AZN
- 47.70%
- NVO
- 42.59%
- LLY
- 22.13%
Dividend Metrics
| Metric | Current stock: JNJ | Industry group median |
|---|---|---|
| Dividend Yield (TTM) | 2.11% | 0.00% |
| Dividend Payout Ratio (TTM) | 60.79% | 0.00% |
Valuation
P/E Ratio (TTM)
Johnson & Johnson (JNJ) trades at P/E ratio of 28.91, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.91
Group distribution
- Max
- 79.93
- Q3
- 47.39
- JNJ
- 28.91
- Median
- 25.31
- Q1
- 15.26
- Min
- 2.05
Largest peers
- ABBV
- 123.72
- LLY
- 40.81
- MRK
- 35.07
- JNJ
- 28.91
- AZN
- 24.76
- NVS
- 21.40
- NVO
- 11.90
P/S Ratio (TTM)
Johnson & Johnson (JNJ) trades at 6.16 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.16
Group distribution
- Max
- 63.16
- Q3
- 28.29
- Median
- 8.07
- JNJ
- 6.16
- Q1
- 3.52
- Min
- 0.01
Largest peers
- LLY
- 14.51
- ABBV
- 7.20
- JNJ
- 6.16
- NVS
- 5.17
- MRK
- 4.74
- AZN
- 4.35
- NVO
- 0.67
P/B Ratio (MRQ)
Johnson & Johnson (JNJ) trades at 7.43 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.43
Group distribution
- Max
- 16.09
- Q3
- 7.48
- JNJ
- 7.43
- Median
- 3.80
- Q1
- 1.72
- Min
- -5.70
Largest peers
- LLY
- 33.66
- NVS
- 7.62
- JNJ
- 7.43
- NVO
- 7.08
- MRK
- 6.80
- AZN
- 5.54
- ABBV
- -67.99
Valuation Metrics
| Metric | Current stock: JNJ | Industry group median |
|---|---|---|
| P/E Ratio (TTM) | 28.91 | 25.31 |
| P/S Ratio (TTM) | 6.16 | 8.07 |
| P/B Ratio (MRQ) | 7.43 | 3.80 |
| Free Cash Flow Yield (TTM) | -- | -2.02% |